While these prior studies are encouraging, a larger study with a more comprehensive group of ALS-mimic disease controls is required in order to verify prior results and determine if CSF cystatin C levels represent a candidate diagnostic biomarker for ALS. Here, CST3 is linked to amyotrophic lateral sclerosis.